
The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.
Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.
[<a href="//storify.com/pharmacytimes/zika" target="_blank">View the story "Response to Zika Virus Spread Highlights Week in Health Care News" on Storify</a>]




